Market Overview

Inside Align Technology's Q2 Beat And Raise: Teen Segment Could See An Inflection Point

Inside Align Technology's Q2 Beat And Raise: Teen Segment Could See An Inflection Point
Related ALGN
8 Biggest Price Target Changes For Thursday
Opinion: Stock-Picking Is A Cult

Align Technology, Inc. (NASDAQ: ALGN) shares soared after reporting record second-quarter results that saw a solid earnings and sales beat.

Align, which is the manufacturer of Invisalign, could see an inflection point in its teen segment, according to a note from Leerink analyst Richard Newitter.

With Align continuing a four-quarter streak of case growth acceleration in its key teen segment, Newitter said there was a lot to like about the quarter earnings beat and above consensus third-quarter guidance revision.

“To us this suggests outreach efforts to go deeper into this market have been paying off and gives us more conviction that growth in the Teen segment could be on the cusp of an inflection,” Newitter said.

After reporting second-quarter teen case start growth of around 38 percent, Newitter believes there's still significant opportunity for Align to increase its presence in the market. Overall sales jumped 32 percent in the quarter.

“Given how under penetrated the company is into this segment relative to its potential we expect the growth momentum will continue into 3Q on the heels of further benefits from recent DTC initiatives,” Newitter add4ed.

Leerink reiterated an Outperform rating and raised its price target from $194 to $199.

Shares of Align Technology closed 10 percent higher at $173.06.

Image credit: Carrie A., Flickr

Latest Ratings for ALGN

Jul 2018Credit SuisseMaintainsOutperformOutperform
Jul 2018Stifel NicolausMaintainsBuyBuy
Jul 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight

View More Analyst Ratings for ALGN
View the Latest Analyst Ratings

Posted-In: Invisalign Leerink Richard NewitterAnalyst Color Price Target Analyst Ratings Best of Benzinga


Related Articles (ALGN)

View Comments and Join the Discussion!

Dynavax Gets 12-1 FDA Vote For Hepatitis B Vaccine

Benzinga's Option Alert Recap From July 28